403 related articles for article (PubMed ID: 31367887)
1. Lp(a): Addressing a Target for Cardiovascular Disease Prevention.
Vasquez N; Joshi PH
Curr Cardiol Rep; 2019 Jul; 21(9):102. PubMed ID: 31367887
[TBL] [Abstract][Full Text] [Related]
2. Apolipoprotein(a) Antisense Oligonucleotides: A New Treatment Option for Lowering Elevated Lipoprotein(a)?
Schreml J; Gouni-Berthold I
Curr Pharm Des; 2017; 23(10):1562-1570. PubMed ID: 28128058
[TBL] [Abstract][Full Text] [Related]
3. Lipoprotein(a), cardiovascular disease, and contemporary management.
Jacobson TA
Mayo Clin Proc; 2013 Nov; 88(11):1294-311. PubMed ID: 24182706
[TBL] [Abstract][Full Text] [Related]
4. Lipoprotein (a): When to Measure and How to Treat?
Rhainds D; Brodeur MR; Tardif JC
Curr Atheroscler Rep; 2021 Jul; 23(9):51. PubMed ID: 34235598
[TBL] [Abstract][Full Text] [Related]
5. Emerging Therapeutic Options for Lowering of Lipoprotein(a): Implications for Prevention of Cardiovascular Disease.
Boffa MB
Curr Atheroscler Rep; 2016 Dec; 18(12):69. PubMed ID: 27761705
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein(a) as a cardiovascular risk factor: current status.
Nordestgaard BG; Chapman MJ; Ray K; Borén J; Andreotti F; Watts GF; Ginsberg H; Amarenco P; Catapano A; Descamps OS; Fisher E; Kovanen PT; Kuivenhoven JA; Lesnik P; Masana L; Reiner Z; Taskinen MR; Tokgözoglu L; Tybjærg-Hansen A;
Eur Heart J; 2010 Dec; 31(23):2844-53. PubMed ID: 20965889
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein(a)-Lowering by 50 mg/dL (105 nmol/L) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study.
Madsen CM; Kamstrup PR; Langsted A; Varbo A; Nordestgaard BG
Arterioscler Thromb Vasc Biol; 2020 Jan; 40(1):255-266. PubMed ID: 31578080
[TBL] [Abstract][Full Text] [Related]
8. Prevention of cardiovascular complications in patients with Lp(a)-hyperlipoproteinemia and progressive cardiovascular disease by long-term lipoprotein apheresis according to German national guidelines.
Klingel R; Heibges A; Fassbender C;
Clin Res Cardiol Suppl; 2017 Mar; 12(Suppl 1):38-43. PubMed ID: 28185214
[TBL] [Abstract][Full Text] [Related]
9. Lipoprotein(a): novel target and emergence of novel therapies to lower cardiovascular disease risk.
Tsimikas S
Curr Opin Endocrinol Diabetes Obes; 2016 Apr; 23(2):157-64. PubMed ID: 26825471
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein(a)-antisense therapy.
Vogt A
Clin Res Cardiol Suppl; 2019 Apr; 14(Suppl 1):51-56. PubMed ID: 30859384
[TBL] [Abstract][Full Text] [Related]
11. Lipoprotein(a) and Atherosclerotic Cardiovascular Disease: Current Understanding and Future Perspectives.
Wu MF; Xu KZ; Guo YG; Yu J; Wu Y; Lin LM
Cardiovasc Drugs Ther; 2019 Dec; 33(6):739-748. PubMed ID: 31655942
[TBL] [Abstract][Full Text] [Related]
12. Role of lipoprotein(a) in atherosclerotic cardiovascular disease: A review of current and emerging therapies.
Alhomoud IS; Talasaz A; Mehta A; Kelly MS; Sisson EM; Bucheit JD; Brown R; Dixon DL
Pharmacotherapy; 2023 Oct; 43(10):1051-1063. PubMed ID: 37464942
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein(a) in clinical practice: New perspectives from basic and translational science.
Scipione CA; Koschinsky ML; Boffa MB
Crit Rev Clin Lab Sci; 2018 Jan; 55(1):33-54. PubMed ID: 29262744
[TBL] [Abstract][Full Text] [Related]
14. Lipoprotein(a) as a potential causal genetic risk factor of cardiovascular disease: a rationale for increased efforts to understand its pathophysiology and develop targeted therapies.
Tsimikas S; Hall JL
J Am Coll Cardiol; 2012 Aug; 60(8):716-21. PubMed ID: 22898069
[TBL] [Abstract][Full Text] [Related]
15. Lipoprotein(a) Management: Pharmacological and Apheretic Treatment.
Hanssen R; Gouni-Berthold I
Curr Med Chem; 2017; 24(10):957-968. PubMed ID: 28078998
[TBL] [Abstract][Full Text] [Related]
16. To test, or not to test: that is the question for the future of lipoprotein(a).
Ellis KL; Chakraborty A; Moses EK; Watts GF
Expert Rev Cardiovasc Ther; 2019 Apr; 17(4):241-250. PubMed ID: 30916582
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein(a) and Cardiovascular Diseases - Revisited.
Jang AY; Han SH; Sohn IS; Oh PC; Koh KK
Circ J; 2020 May; 84(6):867-874. PubMed ID: 32336721
[TBL] [Abstract][Full Text] [Related]
18. Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)
Marcovina SM; Viney NJ; Hughes SG; Xia S; Witztum JL; Tsimikas S
J Clin Lipidol; 2018; 12(1):122-129.e2. PubMed ID: 29174389
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein(a): cardiovascular risk and emerging therapies.
Fujino M; Nicholls SJ
Expert Rev Cardiovasc Ther; 2023 Apr; 21(4):259-268. PubMed ID: 37010028
[TBL] [Abstract][Full Text] [Related]
20. Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans.
Graham MJ; Viney N; Crooke RM; Tsimikas S
J Lipid Res; 2016 Mar; 57(3):340-51. PubMed ID: 26538546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
